摘要
目的分析中晚期肺癌采取盐酸埃克替尼治疗的效果。方法80例中晚期肺癌患者,随机分为观察组和对照组,各40例。观察组采用盐酸埃克替尼治疗,对照组采用常规化疗治疗。比较两组患者临床疗效、免疫功能指标、生活质量评分及不良反应发生情况。结果观察组总有效率67.50%、疾病控制率87.50%均高于对照组的45.00%、67.50%,差异具有统计学意义(P<0.05)。治疗后,观察组CD3^(+)水平为(58.90±11.73)%、CD4^(+)水平为(40.11±5.52)%、CD8^(+)水平为(23.15±6.08)%、CD4^(+)/CD8^(+)水平为(1.72±0.47),对照组CD3^(+)水平为(51.23±11.84)%、CD4^(+)水平为(35.08±6.01)%、CD8^(+)水平为(27.14±6.13)%、CD4^(+)/CD8^(+)水平为(1.28±0.36);治疗后,观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均高于对照组,CD8^(+)水平低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组总体健康评分为(63.27±4.48)分、精力评分为(74.27±4.54)分、社会功能评分为(83.67±3.91)分、心理健康评分为(81.50±4.25)分、躯体疼痛评分为(74.48±6.38)分、躯体角色功能评分为(73.54±4.18)分、情绪角色功能评分为(84.54±3.68)分、躯体健康评分为(71.37±4.28)分,对照组总体健康评分为(54.54±3.25)分、精力评分为(61.22±4.01)分、社会功能评分为(76.34±2.75)分、心理健康评分为(61.24±3.75)分、躯体疼痛评分为(66.58±4.70)分、躯体角色功能评分为(61.22±4.42)分、情绪角色功能评分为(73.05±2.50)分、躯体健康评分为(52.29±2.76)分;治疗后,观察组总体健康、精力、社会功能、心理健康、躯体疼痛、躯体角色功能、情绪角色功能、躯体健康评分均高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率12.50%低于对照组的35.00%,差异有统计学意义(P<0.05)。结论盐酸埃克替尼治疗中晚期肺癌临床效果优于常规化疗,可有效提高患者免疫功能指标,改善患者生活质量,且不良反应较少,值得临床推广。
Objective To analyze the effect of icotinib hydrochloride in the treatment of advanced lung cancer.Methods A total of 80 patients with advanced lung cancer were randomly divided into an observation group and a control group,with 40 cases in each group.The observation group was treated with icotinib hydrochloride,and the control group was treated with conventional chemotherapy.The clinical efficacy,immune function indexes,quality of life score and occurrence of adverse reactions were compared between the two groups.Results The total effective rate of 67.50%and disease control rate of 87.50%in the observation group were higher than those of 45.00%and 67.50%in the control group,and the differences were statistically significant(P<0.05).After treatment,the observation group had CD3^(+)level of(58.90±11.73)%,CD4^(+)level of(40.11±5.52)%,CD8^(+)level of(23.15±6.08)%,CD4^(+)/CD8^(+)level of(1.72±0.47);the control group had CD3^(+)level of(51.23±11.84)%,CD4^(+)level of(35.08±6.01)%,CD8^(+)level of(27.14±6.13)%,CD4^(+)/CD8^(+)level of(1.28±0.36).After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,and the CD8^(+)level was lower than that in the control group.The differences were statistically significant(P<0.05).After treatment,in the observation group,the overall health score was(63.27±4.48)points,the energy score was(74.27±4.54)points,the social function score was(83.67±3.91)points,the mental health score was(81.50±4.25)points,the physical pain score was(74.48±6.38)points,the physical role function score was(73.54±4.18)points,the emotional role function score was(84.54±3.68)points,and the physical health score was(71.37±4.28)points;in the control group,the overall health score was(54.54±3.25)points,the energy score was(61.22±4.01)points,the social function score was(76.34±2.75)points,the mental health score was(61.24±3.75)points,the physical pain score was(66.58±4.70)points,the physical role function score was(61.22±4.42)points,the emotional role function score was(73.05±2.50)points,and the physical health score was(52.29±2.76)points.After treatment,the scores of overall health,energy,social function,mental health,physical pain,physical role function,emotional role function and physical health of the observation group were higher than those of the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions of 12.50%in the observation group was lower than that of 35.00%in the control group,and the difference was statistically significant(P<0.05).Conclusion Icotinib hydrochloride in the treatment of advanced lung cancer is superior to conventional chemotherapy,which can effectively improve patients'immune indexes and improve patients'quality of life,and has fewer adverse reactions,which is worthy of clinical promotion.
作者
倪红梅
NI Hong-mei(Department of Chifeng Hospital,Inner Mongolia,Chifeng 024000,China)
出处
《中国实用医药》
2023年第24期93-96,共4页
China Practical Medicine
关键词
中晚期肺癌
盐酸埃克替尼
免疫功能
不良反应
生活质量
Advanced lung cancer
Icotinib hydrochloride
Immune function
Adverse reactions
Quality of life
